Adjuvant chemotherapy for breast cancer and cognitive impairment.
Complaints of loss of memory and lack of concentration have been reported by long-term survivors of breast cancer. This mild cognitive impairment (MCI), also called "chemobrain" or "chemofog," has been the subject of a number of studies in the last few years. This cognitive impairment, although usually mild, must be studied to define possible risk factors for its development, and for future research into a preventive or therapeutic treatment approach. Long-term survivors of breast cancer must be followed to detect possible treatment sequelae as soon as possible. Since the number of these long-term survivors has increased in the last years, in part because of more active adjuvant treatments, our knowledge about the long-term side effects of these therapies has also grown.
Marín
Alvaro Pinto
AP
Medical Oncology Department, Hospital La Paz, Madrid, Spain. alvaro_pinto_marin@hotmail.com
Sánchez
Andrés Redondo
AR
Arranz
Enrique Espinosa
EE
Auñón
Pilar Zamora
PZ
Barón
Manuel González
MG
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D003072:Cognition Disorders / Q000139:chemically induced* / Q000175:diagnosis; D003863:Depression / Q000150:complications; D005221:Fatigue / Q000150:complications / Q000209:etiology; D005260:Female; D006801:Humans; D009483:Neuropsychological Tests; D017741:Survivors